- Home
- PATH vs NUVL Comparison
PATH vs NUVL Comparison
Compare PATH & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PATH
- NUVL
- Stock Information
- Founded
- PATH 2005
- NUVL 2017
- Country
- PATH United States
- NUVL United States
- Employees
- PATH N/A
- NUVL N/A
- Industry
- PATH Computer Software: Prepackaged Software
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- PATH Technology
- NUVL Health Care
- Exchange
- PATH Nasdaq
- NUVL Nasdaq
- Market Cap
- PATH 6.0B
- NUVL 5.6B
- IPO Year
- PATH 2021
- NUVL 2021
- Fundamental
- Price
- PATH $10.45
- NUVL $71.64
- Analyst Decision
- PATH Hold
- NUVL Strong Buy
- Analyst Count
- PATH 20
- NUVL 9
- Target Price
- PATH $12.91
- NUVL $113.44
- AVG Volume (30 Days)
- PATH 15.2M
- NUVL 703.3K
- Earning Date
- PATH 05-28-2025
- NUVL 05-08-2025
- Dividend Yield
- PATH N/A
- NUVL N/A
- EPS Growth
- PATH N/A
- NUVL N/A
- EPS
- PATH N/A
- NUVL N/A
- Revenue
- PATH $1,429,664,000.00
- NUVL N/A
- Revenue This Year
- PATH $8.98
- NUVL N/A
- Revenue Next Year
- PATH $9.18
- NUVL N/A
- P/E Ratio
- PATH N/A
- NUVL N/A
- Revenue Growth
- PATH 9.30
- NUVL N/A
- 52 Week Low
- PATH $9.38
- NUVL $55.54
- 52 Week High
- PATH $20.95
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- PATH 44.09
- NUVL 52.01
- Support Level
- PATH $10.22
- NUVL $55.54
- Resistance Level
- PATH $11.17
- NUVL $68.45
- Average True Range (ATR)
- PATH 0.60
- NUVL 5.47
- MACD
- PATH 0.09
- NUVL 0.75
- Stochastic Oscillator
- PATH 57.84
- NUVL 93.01
About PATH UiPath Inc.
UiPath Inc offers an end-to-end cross-application enterprise automation platform principally with computer vision technology and user interface automations in its initial RPA offering, which remains the foundation of the platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.